Perimeter sets Aug. 20 call for Q2 2026 results, clarifies May financing tranche
Perimeter Medical Imaging AI will release second-quarter 2026 results on Aug. 20 and hold a webcast call afterward. The company also clarified the final tranche of its May 2026 financing.
Perimeter Medical Imaging AI, Inc. said on Aug. 13 that it will report second-quarter 2026 financial and operating results after market close on Thursday, Aug. 20, then host a webcast and conference call to discuss the results and provide a corporate update.
The company said the call will be its next scheduled update on operations and finances. Perimeter describes itself as a commercial-stage medical technology company and trades on the TSX Venture Exchange under the symbol PINK and on OTCQX as PYNKF.
Perimeter said the conference call will be available by phone in Canada and the United States at 1-800-717-1738, and internationally at 1-646-307-1865. It said the webcast will be broadcast live and archived on its website.
In the same release, Perimeter clarified details of the final tranche of its May 2026 offering. The company said it issued an additional 1,955,500 units at C$0.35 per unit on May 8, generating gross proceeds of C$684,425.
Perimeter said that tranche was the final part of the offering conducted under the listed issuer financing exemption. With that closing, the company said the offering reached its maximum size of 21,489,000 units and C$7,521,150 in gross proceeds.
The company also said it paid an additional cash commission of about C$47,910 and issued 136,885 additional broker warrants in connection with the final tranche.
Perimeter’s release included background on its product, Claire, which it describes as a next-generation AI-enabled device recently approved by the U.S. Food and Drug Administration. The company says the system is intended to be used with physician interpretation and standard methods for evaluating lumpectomy tissue margins in patients with biopsy-confirmed breast cancer.
The release also said the device should not replace histopathology or be used for diagnosis. It listed several patient groups for whom the system is not intended, including people under 18, male patients, patients with metastatic stage IV disease, and others described in the company’s labeling language.
Perimeter said the Aug. 20 call will be archived on its website after the live broadcast. The company also listed investor relations and chief executive contact information in the release.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()